Celcuity initiated with bullish view at H.C. Wainwright, here’s why

H.C. Wainwright initiated coverage of Celcuity with a Buy rating and $27 price target. Celcuity is a clinical stage company developing novel therapies for the treatment of cancer, the analyst tells investors in a research note. The firm estimates a market opportunity of nearly $12B just for gedatolisib’s two initial indications. The drug also has potential to be an effective therapy for multiple solid tumors, such as ovarian, endometrial, small cell lung and pancreatic cancers, says the firm.